Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose, food effect, and minidose bioavailability study of BCI-838 and BCI-632 prodrugs in healthy male volunteers
NL-OMON35311Active, not recruiting
- Sponsor
- BrainCells Inc.
- Start
- Oct 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of BCI-838, BCI-1038, BI-1206 and BCI-1283 in major depressive disorder (MDD) and affective disorder (3 arms), sponsored by BrainCells Inc. Primary endpoints: Safety and tolerability, Pharmacokinetics of BCI-838 and 3 more. Started Oct 2011; status: active, not recruiting.
02
Drugs
BCI-838BCI-1038BI-1206BCI-1283
03
Conditions
major depressive disorder (MDD)affective disorder
Beyond the preview
Go deeper on NL-OMON35311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35311.